glp-1 and dual glp-1/gip receptor agonists GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Understanding GLP-1 receptor agonists and
Description
Most patients start seeing results around 12 weeks into treatment

The 2020 Standards of Medical Care include some notable updates related to patient-centered care and the use of glucose-lowering agents

329,330 In degenerative joint diseases like OA, the metabolic balance of chondrocytes is disrupted, leading to the overproduction of degrading enzymes and inflammatory mediators, including iNOS, MMP-13, and ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5), which participate in cartilage degradation and inflammatory processes

The Low and Slow Titration Schedule Standard titration increases the dose every four weeks

Clinicians should provide clear, evidence-based information, set realistic timelines, and explain uncertainties to avoid overpromising results

However, there some key differences in the weight loss impacts between the 2 treatments
